AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11557836 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 108
Study 11557836 — intervention group
Group type: COMPARATOR
Intervention: Placebo effects
Number of subjects: 108
Study 11557836 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle treatments
Number of subjects: 108
Study 9263089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (600,000 U in total)
Number of subjects: 18
Study 9263089 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 18
Study 8427943 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocapril HCl (0.5 mg)
Number of subjects: 6
Study 8427943 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocapril HCl (1.0 mg)
Number of subjects: 6
Study 8427943 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocapril HCl (2.0 mg)
Number of subjects: 6
Study 8427943 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocapril HCl
Number of subjects: 6
Study 3326213 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated microspheres of pancreatin
Number of subjects: 23
Study 3326213 — intervention group
Group type: COMPARATOR
Intervention: Standard enteric coated preparation
Number of subjects: 23
Study 29253350 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosaicplasty
Number of subjects: 40
Study 29253350 — intervention group
Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 40
Study 29253350 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study 26692449 — intervention group
Group type: COMPARATOR
Intervention: Continuous CS-UCS pairings (C-C)
Number of subjects: 0
Study 26692449 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial followed by continuous CS-UCS pairings (P-C)
Number of subjects: 0
Study 26692449 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous followed by partial CS-UCS pairings (C-P)
Number of subjects: 0
Study 26692449 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial CS-UCS pairings during acquisition (P-P)
Number of subjects: 0
Study 25910983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (goal for steps taken per day)
Number of subjects: 55
Study 25910983 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific goal for steps taken)
Number of subjects: 55
Study 23002086 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval-walking group
Number of subjects: 32
Study 23002086 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 23002086 — intervention group
Group type: COMPARATOR
Intervention: Continuous-walking group
Number of subjects: 32
Study 20639713 — intervention group
Group type: EXPERIMENTAL
Intervention: Muffins containing 4 mg Fe as ferrous fumarate with orange juice (25 mg ascorbic acid)
Number of subjects: 21
Study 20639713 — intervention group
Group type: COMPARATOR
Intervention: Muffins containing 4 mg Fe as ferrous fumarate with apple juice (no ascorbic acid)
Number of subjects: 21
Study 18348735 — intervention group
Group type: EXPERIMENTAL
Intervention: Narconon drug education curriculum
Number of subjects: 1000
Study 18348735 — intervention group
Group type: COMPARATOR
Intervention: Control group (received drug education after the six-month follow-up)
Number of subjects: 1000
Study 17288232 — intervention group
Group type: EXPERIMENTAL
Intervention: Antinicotine vaccines (TA-NIC, NicVAX, CYT002-NicQb)
Number of subjects: 0
Study 12707149 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (n = 16) at doses of up to 70 mL x kg(‐1) x d(‐1)
Number of subjects: 31
Study 12707149 — intervention group
Group type: COMPARATOR
Intervention: HES 200/0.5 (n = 15) at doses of up to 33 mL x kg(‐1) x d(‐1) followed by human albumin
Number of subjects: 31
Study 12707149 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (n = 16)
Number of subjects: 31
Study 11032216 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodized multiple-set resistance training
Number of subjects: 24
Study 11032216 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-set circuit resistance training
Number of subjects: 24
Study 11032216 — intervention group
Group type: COMPARATOR
Intervention: No resistance exercise control group
Number of subjects: 24
Study 9321529 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (induction treatment)
Number of subjects: 346
Study 9321529 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (daunorubicin plus cytarabine) (induction treatment)
Number of subjects: 346
Study 9321529 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (maintenance treatment)
Number of subjects: 346
Study 9321529 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (maintenance treatment)
Number of subjects: 346
Study 9321529 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (induction and maintenance treatment)
Number of subjects: 346
Study 8416719 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient chemotherapy
Number of subjects: 259
Study 3546124 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diclofenac (prostaglandin inhibitor) for 1 week after splintage removal
Number of subjects: 0
Study 3546124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30230538 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent group contingency
Number of subjects: 9
Study 30230538 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized dependent group contingency
Number of subjects: 9
Study 30230538 — intervention group
Group type: COMPARATOR
Intervention: Independent group contingency and Randomized dependent group contingency
Number of subjects: 9
Study 27701369 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaortic approach (TAo)
Number of subjects: 242
Study 27701369 — intervention group
Group type: COMPARATOR
Intervention: Transaxillary approach (TAx)
Number of subjects: 242
Study 26520217 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered exposure (EX)
Number of subjects: 47
Study 26520217 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA)
Number of subjects: 47
Study 26520217 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list (Control)
Number of subjects: 47
Study 23797378 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve block (PNB) using computer-controlled local anesthetic delivery (CCLAD)
Number of subjects: 50
Study 23797378 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia
Number of subjects: 50
Study 21785360 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional consent (n = 110)
Number of subjects: 323
Study 21785360 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary consent (n = 103)
Number of subjects: 323
Study 21785360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiered consent (n = 110)
Number of subjects: 323
Study 21785360 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 323
Study 19359651 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent respiratory tract infections
Number of subjects: 105
Study 19359651 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired respiratory tract infections
Number of subjects: 105
Study 19359651 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory tract infections in the 3 months before an atherothrombotic ischemic event
Number of subjects: 105
Study 19359651 — intervention group
Group type: EXPERIMENTAL
Intervention: History of respiratory infection in the prior year
Number of subjects: 105
Study 19359651 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell count
Number of subjects: 105
Study 16963784 — intervention group
Group type: EXPERIMENTAL
Intervention: JUMP-in intervention
Number of subjects: 510
Study 16963784 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 510
Study 14754980 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (first-generation antihistamine)
Number of subjects: 24
Study 14754980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (second-generation antihistamine)
Number of subjects: 24
Study 14754980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11111965 — intervention group
Group type: EXPERIMENTAL
Intervention: Converted group (early conversion from MMF to azathioprine at 4 months)
Number of subjects: 28
Study 11111965 — intervention group
Group type: COMPARATOR
Intervention: Control group (late conversion from MMF to azathioprine after 12 months)
Number of subjects: 28
Study 9379690 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (4 months therapy)
Number of subjects: 32
Study 9379690 — intervention group
Group type: COMPARATOR
Intervention: Control (surgical resection only)
Number of subjects: 32
Study 8406966 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐phase gutta‐percha on a plastic Thermafil carrier
Number of subjects: 51
Study 8406966 — intervention group
Group type: COMPARATOR
Intervention: standard beta‐phase gutta‐percha with lateral condensation
Number of subjects: 51
Study 8406966 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (Thermafil and lateral condensation)
Number of subjects: 51
Study 3022664 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 21
Study 3022664 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine-yohimbine
Number of subjects: 21
Study 3022664 — intervention group
Group type: COMPARATOR
Intervention: Desipramine-lithium carbonate or lithium carbonate-tranylcypromine sulfate combination treatment
Number of subjects: 21
Study 31599351 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + treatment as usual (TAU)
Number of subjects: 25
Study 31599351 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 25
Study 30224269 — intervention group
Group type: EXPERIMENTAL
Intervention: Calmer Life (CL)
Number of subjects: 0
Study 30224269 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Community Care with Resource Counseling (ECC-RC)
Number of subjects: 0
Study 26647769 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sleep (21.00-07.00 h time in bed, EXT)
Number of subjects: 14
Study 26647769 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (22.30-07.00 h time in bed, HAB)
Number of subjects: 14
Study 26647769 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (24 h and 34 h of continuous awakening)
Number of subjects: 14
Study 25263836 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lifestyle modification programme (specific health guidance)
Number of subjects: 3480
Study 25263836 — intervention group
Group type: COMPARATOR
Intervention: 1% to <3% weight reduction group
Number of subjects: 3480
Study 25263836 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% to <5% weight reduction group
Number of subjects: 3480
Study 25263836 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥5% weight reduction group
Number of subjects: 3480
Study 22864399 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence on the stress-challenge task before initiating buprenorphine treatment
Number of subjects: 48
Study 22864399 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant and placebo groups
Number of subjects: 48
Study 19350648 — intervention group
Group type: EXPERIMENTAL
Intervention: Body image intervention (3 sessions of 50 minutes each)
Number of subjects: 194
Study 19350648 — intervention group
Group type: COMPARATOR
Intervention: Usual classes (Control)
Number of subjects: 194
Study 18056186 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (first-line)
Number of subjects: 53
Study 18056186 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (second-line)
Number of subjects: 53
Study 18056186 — intervention group
Group type: COMPARATOR
Intervention: Sustained detectable BCR-ABL (control group)
Number of subjects: 53
Study 15854186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cophenylcaine nasal spray
Number of subjects: 98
Study 15854186 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 98
Study 12162475 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-coated tablets (FCT)
Number of subjects: 16
Study 12162475 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous solution (AS)
Number of subjects: 16
Study 12884889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 158
Study 12884889 — intervention group
Group type: COMPARATOR
Intervention: Clinical management (Control)
Number of subjects: 158
Study 10336001 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 0
Study 10336001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10336001 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin-labeled platelets
Number of subjects: 0
Study 1984901 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal Doppler color flow imaging
Number of subjects: 42
Study 1984901 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic Doppler color flow imaging
Number of subjects: 42
Study 6411230 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin infusion starting at 2 U/hour for adolescents, 4 U/hour for adults, and 6 U/hour for patients with acromegaly
Number of subjects: 25
Study 6411230 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin infusion
Number of subjects: 25
Study 31957345 — intervention group
Group type: EXPERIMENTAL
Intervention: Saudi Diabetes Risk Score (SADRISC)
Number of subjects: 1403
Study 31957345 — intervention group
Group type: EXPERIMENTAL
Intervention: SADRISC
Number of subjects: 1403
Study 30582194 — intervention group
Group type: EXPERIMENTAL
Intervention: Media Smart-Targeted (MS-T) program (9-module program released weekly)
Number of subjects: 316
Study 30582194 — intervention group
Group type: COMPARATOR
Intervention: Positive body image tips (control group)
Number of subjects: 316
Study 28477269 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires regarding awareness and knowledge of cervical cancer
Number of subjects: 450
Study 28477269 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires regarding attitudes towards cervical cancer screening and prevention
Number of subjects: 450
Study 28477269 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall awareness and knowledge assessment
Number of subjects: 450
Study 28477269 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall attitude assessment
Number of subjects: 450
Study 23623564 — intervention group
Group type: EXPERIMENTAL
Intervention: HF symptom training intervention
Number of subjects: 99
Study 23623564 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study 21737382 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional mental practice during the interval between the two training sessions
Number of subjects: 40
Study 21737382 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard training without additional mental practice)
Number of subjects: 40
Study 19842422 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/PVM/MA copolymer mouthrinse
Number of subjects: 0
Study 17426065 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF treatments (etanercept, infliximab, adalimumab) in RCTs
Number of subjects: 0
Study 17426065 — intervention group
Group type: EXPERIMENTAL
Intervention: DREAM patients eligible for RCTs
Number of subjects: 0
Study 17426065 — intervention group
Group type: COMPARATOR
Intervention: DREAM patients
Number of subjects: 0
Study 15115499 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA (twice weekly for 3 months)
Number of subjects: 16
Study 15115499 — intervention group
Group type: COMPARATOR
Intervention: ECP (once monthly for 6 months at relapse)
Number of subjects: 16
Study 11962245 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Frequency Questionnaire (FFQ)
Number of subjects: 104
Study 11962245 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour recall
Number of subjects: 104
Study 11962245 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day food records
Number of subjects: 104
Study 11962245 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional correlation testing
Number of subjects: 104
Study 11962245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontraditional method
Number of subjects: 104
Study 9149168 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus surgery plus radiotherapy (arm A)
Number of subjects: 92
Study 9149168 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus radiotherapy alone (arm B)
Number of subjects: 92
Study 7955803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethoxyidazoxan 6 micrograms/kg
Number of subjects: 6
Study 7955803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethoxyidazoxan 8 micrograms/kg
Number of subjects: 6
Study 7955803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3602266 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 125 mg
Number of subjects: 36
Study 3602266 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg
Number of subjects: 36
Study 3602266 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 mg)
Number of subjects: 36
Study 29380026 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma stress at baseline
Number of subjects: 186
Study 29380026 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-stigma interventions
Number of subjects: 186
Study 27914503 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with Edwards SAPIEN 3 Transcatheter Heart Valve plus optimal heart failure therapy (OHFT)
Number of subjects: 600
Study 27914503 — intervention group
Group type: COMPARATOR
Intervention: Optimal heart failure therapy (OHFT) alone
Number of subjects: 600
Study 25148183 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear-wave elastography at biopsy site
Number of subjects: 50
Study 25148183 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear-wave elastography at ipsilateral lobe
Number of subjects: 50
Study 25148183 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear-wave elastography at contralateral lobe
Number of subjects: 50
Study 25148183 — intervention group
Group type: COMPARATOR
Intervention: Steatosis and serum markers
Number of subjects: 50
Study 23233021 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (1 mg daily)
Number of subjects: 60
Study 23233021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20826632 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling (LC)
Number of subjects: 283
Study 20826632 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling + Flaxseed (LCF) 30 g/d
Number of subjects: 283
Study 20826632 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling + Walnuts (LCW) 30 g/d
Number of subjects: 283
Study 20826632 — intervention group
Group type: COMPARATOR
Intervention: Control Group (LC)
Number of subjects: 283
Study 18458842 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide
Number of subjects: 10
Study 18458842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16398803 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin (GTN)
Number of subjects: 40
Study 16398803 — intervention group
Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 40
Study 14514130 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg LJP 394 weekly for 16 weeks followed by three 12-week treatment cycles of 50 mg LJP 394 weekly
Number of subjects: 179
Study 14514130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 14514130 — intervention group
Group type: EXPERIMENTAL
Intervention: LJP 394
Number of subjects: 179
Study 10571358 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop haptic IOL
Number of subjects: 48
Study 10571358 — intervention group
Group type: COMPARATOR
Intervention: Plate haptic IOL
Number of subjects: 48
Study 8991843 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ethanol added to distension medium during ablative hysteroscopy
Number of subjects: 120
Study 8991843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ethanol monitoring
Number of subjects: 120
Study 8991843 — intervention group
Group type: COMPARATOR
Intervention: Procedures with minimal endometrial injury (e.g., syneciolysis, hysteroscopic proximal tubal catheterisation)
Number of subjects: 120
Study 8991843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative procedures (e.g., resection of myoma, endometrium ablation, septum resection)
Number of subjects: 120
Study 8991843 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath alcohol, amount of absorbed fluid, haematocrit and haemoglobin values, central venous pressure, heart frequency
Number of subjects: 120
Study 10147023 — intervention group
Group type: EXPERIMENTAL
Intervention: Early thrombolysis (less than 3 hours)
Number of subjects: 167
Study 10147023 — intervention group
Group type: COMPARATOR
Intervention: Late thrombolysis (greater than 3 hours)
Number of subjects: 167
Study 10147023 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis for posterior infarcts
Number of subjects: 167
Study 10147023 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis for anterior infarcts
Number of subjects: 167
Study 10147023 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life post-AMI
Number of subjects: 167
Study 6696208 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 65 micrograms
Number of subjects: 13
Study 6696208 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 250 micrograms
Number of subjects: 13
Study 30951926 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial participation for newly diagnosed glioblastoma (nGBM)
Number of subjects: 755
Study 30951926 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial participation for recurrent glioblastoma (rGBM)
Number of subjects: 755
Study 30951926 — intervention group
Group type: COMPARATOR
Intervention: Trial eligible but received standard care
Number of subjects: 755
Study 30951926 — intervention group
Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 755
Study 30951926 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics of nGBM trial participants
Number of subjects: 755